Accelerating discovery of liver disease mechanisms
A University of Edinburgh team used Google Co-Scientist to study MASH liver disease, integrating liver biology and pharmacology evidence to identify the NLRP3 inflammasome as a key molecular bridge between inflammation and metabolism. This explains why resmetirom works for only a minority of eligible patients. The experimentally validated hypothesis could advance targeted dual therapies.